Heiberg, M S <br/><br/>
Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicentre study.  [electronic resource] 

 -  Annals of the rheumatic diseases  Oct 2006 
 - 1379-83 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase IV; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0003-4967 
<br/><br/><label>Standard No.: </label>10.1136/ard.2006.051540  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab<br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Antirheumatic Agents--adverse effects<br/>Arthritis, Rheumatoid--drug therapy<br/>Drug Therapy, Combination<br/>Female<br/>Humans<br/>Longitudinal Studies<br/>Male<br/>Methotrexate--adverse effects<br/>Middle Aged<br/>Severity of Illness Index<br/>Treatment Outcome<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors